Women's healthcare vendor Hologic said that researchers have found promising five-year results from the American Society of Breast Surgeons (ASBS) MammoSite Breast Brachytherapy Registry Trial.
Of the 1,449 patients (1,440 treated with MammoSite) with early-stage breast cancer in the registry, 37 patients had an ipsilateral breast tumor recurrence, for a five-year actuarial rate of 3.8%. In addition, a subset analysis of the first 400 consecutive cases had a median follow-up of 60.5 months and showed a five-year actuarial rate for ipsilateral breast tumor recurrence of 3.04%, Hologic of Bedford, MA, said.
The study was published in the International Journal of Radiation Oncology, Biology, Physics.
Related Reading
FDA panel gives nod to Hologic tomosynthesis PMA, September 24, 2010
FDA panel to review Hologic tomo unit, September 23, 2010
Hologic completes Sentinelle acquisition, August 6, 2010
Hologic grows sales, though profit slips, August 2, 2010
Hologic secures panel date for tomo PMA, July 27, 2010
Copyright © 2010 AuntMinnie.com
